Truist lowered the firm’s price target on Progyny (PGNY) to $28 from $34 and keeps a Buy rating on the shares after its Q4 results and below-consensus guide. The shortfall in covered lives reignited investor concerns about broader layoffs and employer demand trends potentially affecting Progyny’s growth trajectory, though the firm does not believe there has been any fundamental shift in the company’s top-line growth trajectory or demand environment, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny price target lowered to $28 from $32 at KeyBanc
- Midday Fly By: Paramount wins Warner bidding, Amazon to invest $5oB in OpenAI
- Closing Bell Movers: Netflix up 10% after backing away from Warner deal
- Progyny Posts Strong Q4 Results and 2026 Growth Outlook
- Progyny reports Q4 adjusted EPS 48c, consensus 40c